402 related articles for article (PubMed ID: 11442758)
1. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
2. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.
Showe LC; Fox FE; Williams D; Au K; Niu Z; Rook AH
J Immunol; 1999 Oct; 163(7):4073-9. PubMed ID: 10491012
[TBL] [Abstract][Full Text] [Related]
3. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
4. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.
Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M
Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208
[TBL] [Abstract][Full Text] [Related]
5. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
6. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
7. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of IL-7 and IL-12 on human T cell activation.
Mehrotra PT; Grant AJ; Siegel JP
J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
[TBL] [Abstract][Full Text] [Related]
9. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
10. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course.
Wu R; Zippin JH; Magro C
Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies.
Tendler CL; Burton JD; Jaffe J; Danielpour D; Charley M; McCoy JP; Pittelkow MR; Waldmann TA
Cancer Res; 1994 Aug; 54(16):4430-5. PubMed ID: 7913876
[TBL] [Abstract][Full Text] [Related]
12. Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
Abrams JT; Ghosh SK; DeFreitas E
Cancer Res; 1993 Nov; 53(22):5501-6. PubMed ID: 8221690
[TBL] [Abstract][Full Text] [Related]
13. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
14. Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor.
Magazin M; Poszepczynska-Guigné E; Bagot M; Boumsell L; Pruvost C; Chalon P; Culouscou JM; Ferrara P; Bensussan A
J Invest Dermatol; 2004 Jan; 122(1):111-8. PubMed ID: 14962098
[TBL] [Abstract][Full Text] [Related]
15. Priming for high interferon-gamma production induced by interleukin-12 in both CD4+ and CD8+ T cell clones from HIV-infected patients.
Paganin C; Frank I; Trinchieri G
J Clin Invest; 1995 Sep; 96(3):1677-82. PubMed ID: 7657839
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.
Gollob JA; Schnipper CP; Orsini E; Murphy E; Daley JF; Lazo SB; Frank DA; Neuberg D; Ritz J
J Clin Invest; 1998 Aug; 102(3):561-75. PubMed ID: 9691093
[TBL] [Abstract][Full Text] [Related]
17. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
18. Expression of interleukin 12 receptor (IL-12R) and IL-18R on CD4+ T cells from patients with rheumatoid arthritis.
Aita T; Yamamura M; Kawashima M; Okamoto A; Iwahashi M; Yamana J; Makino H
J Rheumatol; 2004 Mar; 31(3):448-56. PubMed ID: 14994387
[TBL] [Abstract][Full Text] [Related]
19. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).
Vonderheid EC; Bigler RD; Kotecha A; Boselli CM; Lessin SR; Bernengo MG; Polansky M
J Invest Dermatol; 2001 Sep; 117(3):654-62. PubMed ID: 11564173
[TBL] [Abstract][Full Text] [Related]
20. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
